"BANTING Confirms Evolocumab Benefits in Type 2 Diabetes" - Eleanor McDermid
The potent lipid-lowering effects of the PCSK9 inhibitor evolocumab have been demonstrated in a randomized trial conducted specifically in people with type 2 diabetes. The cardioprotective effect of evolocumab has already been shown in a prespecified analysis of 40 percent of the FOURIER cohort that had type 2 diabetes. The BANTING trial tested the lipid-lowering efficacy in 421 people who all had type 2 diabetes plus hypercholesterolemia or mixed dyslipidemia at baseline and were already taking a statin. Robert Rosenson, MD, professor of medicine, cardiology, and director of Cardiometabolic disorders at the Icahn School of Medicine at Mount Sinai and co-researchers note in Diabetologia that evolocumab was well tolerated, but caution that the short follow-up “limited the ability to assess long-term safety and durability of response.”
— Robert Rosenson, MD, Professor, Medicine, Cardiology, Director, Cardiometabolic Disorders, Icahn School of Medicine at Mount Sinai
